Thanks for reading Neural Pharm! Subscribe for free to receive new posts and support my work.
References:
Cassels B, et al. Dark classics in chemical neuroscience: mescaline. ACS Publications. 9 Sept 2018. https://pubs.acs.org/doi/10.1021/acschemneuro.8b00215
Dinis-Oliveira RJ, et al. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. 1 Aug 2019. Current Molecular Pharmacology.https://www.ingentaconnect.com/contentone/ben/cmp/2019/00000012/00000003/art00003
Engel L, et al. Mescaline, peyote, and San Pedro: is sustainability important for cacti consumers? 18 Aug 2023. Journal of Psychedelic Studies. https://akjournals.com/view/journals/2054/7/2/article-p135.xml
Jay M. A Century of mescaline. Chacruna. 30 April 2021. https://chacruna.net/century_of_mescaline/
Kolaczynska K, et al. Receptor interaction profiles of 4-alkoxy-3,5-dimethoxy-phenylethylamines (mescaline derivatives) and related amphetamines. Frontiers in Pharmacology. 8 Feb 2022. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.794254/full
Pollan, Michael. This is Your Mind on Plants. 2021. Penguin Press. New York.
Uthang MV, et al. The epidemiology of mescaline use: pattern for use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. 5 May 2021. British Association for Psychopharmacology. https://journals.sagepub.com/doi/full/10.1177/02698811211013583
Get full access to Neural Pharm at neuralpharm.substack.com/subscribe